New York Life Investment Management’s Astria Therapeutics ATXS Stock Holding History

New York Life Investment Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-31,631	Closed	-$414K	–	785
2025 Q4	$414K	Buy	+31,631	New	+$378K	﹤0.01%	741

New York Life Investment Management's ATXS Position: Q1 2026 in Review

New York Life Investment Management sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 31,631 shares — an estimated $414K sold.

New York Life Investment Management first reported a position in ATXS in Q4 2025 and held it in 1 quarter. The position peaked at $414K in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

New York Life Investment Management reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
New York Life Investment Management sold 31,631 Astria Therapeutics shares in Q1 2026, an estimated $414K.
New York Life Investment Management first reported a position in Astria Therapeutics in Q4 2025 and held it in 1 quarter.
New York Life Investment Management's Astria Therapeutics position peaked at $414K in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on New York Life Investment Management's 13F filing for Q1 2026, filed 7 May 2026.